Canaccord Genuity Reiterates a 'Buy' on Dendreon (DNDN); Targeting the Urologist Provenge Customer
Tweet
Share
E-mailGet Alerts DNDN Hot Sheet
Price: $0.13 --0%
Rating Summary:
2 Buy, 15 Hold, 9 Sell
Rating Trend: = Flat
Today's Overall Ratings:
Up: 13 | Down: 14 | New: 11
Rating Summary:
2 Buy, 15 Hold, 9 Sell
Rating Trend: = Flat
Today's Overall Ratings:
Up: 13 | Down: 14 | New: 11
Join SI Premium – FREE
Canaccord Genuity reiterates a 'Buy' on Dendreon (NASDAQ: DNDN), PT $65.
Canaccord analyst says, "Following meetings we hosted last Friday with
institutional investors and Dendreon CEO Mitchell Gold, we remain positive on
the long-term commercial potential of Provenge and would be buying shares on recent weakness."
"Reiterated guidance calls for an average of 1-2 patients treated per month per
center per 12 workstations. With 48 FDA-approved stations and room for
efficiency improvements, we model for $367M in Provenge sales for 2011, in
line with guidance of $350-400M."
For more ratings news on Dendreon click here and for the rating history of Dendreon click here.
Shares of Dendreon closed at $36.86 yesterday.
Canaccord analyst says, "Following meetings we hosted last Friday with
institutional investors and Dendreon CEO Mitchell Gold, we remain positive on
the long-term commercial potential of Provenge and would be buying shares on recent weakness."
"Reiterated guidance calls for an average of 1-2 patients treated per month per
center per 12 workstations. With 48 FDA-approved stations and room for
efficiency improvements, we model for $367M in Provenge sales for 2011, in
line with guidance of $350-400M."
For more ratings news on Dendreon click here and for the rating history of Dendreon click here.
Shares of Dendreon closed at $36.86 yesterday.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Fiserv (FISV) PT Lowered to $60 at Freedom Broker
- UBS Reiterates Buy Rating on Hilton Worldwide (HLT)
- JD.com (JD) Reiterated at Buy by Benchmark Amid Earnings Recovery
Create E-mail Alert Related Categories
Analyst CommentsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
